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domized clinical trials (RCTs), with follow-up times from 1 to 36months. Efficacy at
three months of follow-up (estimated as the posterior median) ranged from 87.5%
for the levonorgestrel-releasing intrauterine system (LNG-IUS) to 14.2% for proges-
togens administered for less than twoweeks out of four in themenstrual cycle. The
95% credible intervals for most estimates were quite wide, mainly because of the
limited evidence formany combinations of treatment class and follow-up time and
the uncertainty from estimating %MBL80mL from other outcome data.
CONCLUSIONS: LNG-IUS and endometrial ablation have high efficacy for HMB. The
study yielded useful insights on MTC in sparse evidence networks. Diversity of
outcome measures and follow-up times in the HMB literature presented consider-
able challenges. The Bayesian credible intervals reflected the various sources of
uncertainty.
PIH4
IS SILDENAFIL – APOMORPHINE SUBLINGUAL COMBINATION SIGNIFICANTLY
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OBJECTIVES: To test the efficacy of a sildenafil (50 mg) and apomorphine (3 mg)
sublingual combination in treatingmale Erectile Dysfunction (ED) in comparison to
sublingual sildenafil (50 mg) that shows an increasing number of non-responders.
METHODS: In all, 50 eligible ED patients were enrolled into a prospective single-
blinded crossover study with two treatment periods, each of 4 weeks, separated by
a 2-weekwashout period. A randomization list in blocks in closed packetswas used
to randomize the patients to receive sildenafil then the combination or the combi-
nation then sildenafil. The primary efficacy endpoint was the percent of attempts
resulting in erection firmenough for intercourse. Other efficacy endpoints included
the percent of attempts resulting in successful intercourse, change in the score of
the 5-item version of the International Index of Erectile Function (IIEF-5) from
baseline, response to Sexual Encounter Profile (SEP) diary questions 2 and 3, and
patient’s preference (Of the two study interventions, which one did you prefer?).
RESULTS: Only 43 patients completed the whole schedule and had results evalu-
able for efficacy. Sildenafil - apomorphine combination had a significantly higher
estimate than sildenafil in regard to the mean percent of attempts resulting in
erection firm enough for intercourse (77.6% vs. 63.1%, p 0.001) and resulting in
successful intercourse (51.1% vs. 34%, p 0.001), as well as erectile function as
evaluated by the change in the median IIEF-5 score from baseline (18 vs. 15 with
baseline of 7, P0.001). Also, the proportion of affirmative answers regarding the
SEP diary was significantly higher after the combination (question 2: 79.1% vs.
55.8% P0.01 and question 3: 65.1% vs. 44.2%, P0.05). At the end of the study,
patient preference was 88.4% for the combination and 4.6% for sildenafil.
CONCLUSIONS: Sildenafil - apomorphine sublingual combinationwas significantly
more effective than sublingual sildenafil in treating ED.
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OBJECTIVES: Benign prostatic hyperplasia (BPH) is a chronic, progressive disease
with important healthcare and economic implications. 5-alpha reductase inhibi-
tors (5-ARIs), dutasteride and finasteride are effective treatments. If untreated, BPH
may lead to complications such as acute urinary retention (AUR) and the need for
surgery (NfS). The aim of this review is to compare the efficacy of dutasteride and
finasteride in reducing episodes of AUR and the NfS related to BPH. METHODS:
MEDLINE, Lilacs and the Cochrane Central Register of Controlled Trials were
searched (from inception to September 2011) to retrieve randomized clinical trials
(RCTs) and observational studies evaluating these drugs. The search included ar-
ticles published in English, Portuguese, and Spanish. Patients with confirmed di-
agnosis of BPH were included. We analyzed data from studies that reported the
number of AUR or NfS following treatment with dutasteride or finasteride.
RESULTS:The literature search identified 24 potential full-text publications; 9 RCTs
(where 9were duplicates) and 6 observational/ retrospective studies. No RCT head-
to-head comparison was found. Indirect efficacy comparison between the two
5-ARIs, based on RCTs, was deemed inappropriate due to the heterogeneity of the
patients included in the trials, differences in outcomemeasurements, study design
and combination therapies (i.e., alpha blockers) used in the studies. Direct com-
parison of dutasteride and finasteride was available from 3 retrospective cohort
studies, indicating that dutasteridemay bemore effective in reducing the episodes
of AUR (Odds ratio0.79; 95%CI0.68-0.93; p0.0042) and the NfS (Odds ratio0.77;
95%CI0.61-0.98; p0.03) relative to finasteride. CONCLUSIONS: The current evi-
dence on the efficacy of dutasteride and finasteride makes an indirect comparison
between the two 5-ARIs difficult; however, data retrieved from observational stud-
ies indicate improved clinical performance of dutasteride compared to finasteride.
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Aparasu RR, Chatterjee S
University of Houston, Houston, TX, USA
OBJECTIVES: Antipsychotic agents are often used for behavioral symptoms of de-
mentia and psychoses. This study evaluated the risk of nursing home admission
associated with use of antipsychotics among community-dwelling (Medicare and
Medicaid) dual eligible beneficiaries in the United States. METHODS: The study
involved a retrospective cohort design matched on propensity score using Medi-
care and Medicaid Analytical eXtract (MAX) data from four US states. The study
population included all elderly dual eligible community dwelling beneficiaries
(aged  65 years) who initiated antipsychotics anytime during July 1, 2001 and
December 31, 2003. Antipsychotic users were followed till the occurrence of nurs-
ing home admission or, end of the study period, whichever occurred earlier. The
risk of nursing home admission was modeled using Cox proportional model and
extended Cox hazardmodel stratified onmatched pairs based on propensity score,
using typical agents as the reference category. RESULTS: Analysis of Medicaid-
Medicare community dwelling dual eligible data revealed that there were 88,989
antipsychotic users (47,090 atypical and 41, 919 typical users) in the unmatched
cohort and 60,840 users in the matched cohort (30,420 atypical and 30, 420 typical
users). The unadjusted rate of nursing home admission was 20.58% (6, 260) in the
atypical cohort and 16.15% (4, 914) in the typical cohort. The results of Cox regres-
sion [average HR, 1.29; 95% CI, 1.23 -1.34] as well as extended regression [40days:
HR, 1.15; 1.08-1.23 and40 days: HR, 1.42; 1.33-1.51] suggest that, the risk of nursing
home admission was higher among atypical users compared to typical users.
CONCLUSIONS: The higher risk of nursing home admission among atypical users
compared to typical users may be attributable to indication bias. Since atypical
antipsychotics are often used to control behavioral symptoms of dementia, it is
possible that patients with behavioral symptoms treatedwith atypical agents were
subsequently admitted to nursing homes.
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OBJECTIVES: Previous studies have reported differential safety and efficacy profiles
of typical and atypical antipsychotics in the elderly. The study compared the risk of
all-cause hospitalization among elderly dual eligible beneficiaries (Medicare and
Medicaid) using typical and atypical antipsychotic agents.METHODS: A retrospec-
tive cohort study designmatched on propensity scorewas used to examine the risk
of all-cause hospitalization amongdual eligible beneficiaries 65 years or older using
antipsychotic agents. The study involved use of Medicare and Medicaid Analytical
eXtract (MAX) data from four US states. New antipsychotic users were followed for
up to six months without any censoring. The risk of hospitalization was modeled
using Cox proportional model and extended Cox hazard model stratified on
matched pairs based on propensity score. RESULTS: Analysis of Medicaid-Medi-
care dual eligible data revealed that, therewere 1, 43, 617 newantipsychotic (91, 665
atypical and 51, 952 typical) users in the unmatched cohort and 84, 162 (42,081
atypical and 42,081 typical) users in the matched cohort. The unadjusted rates of
hospitalization were 27.17% and 27.96% among atypical and typical users respec-
tively. Cox hazards regression found that, users of typical antipsychotics were
marginally at a higher average risk of hospitalization compared to atypical users
[Hazard Ratio, (HR), 1.07; 95% Confidence Interval, (CI), 1.04-1.10]. Results of ex-
tended Cox regression suggest that, typical users had a higher risk of hospitaliza-
tion than atypical users within the initial 40 days of therapy [HR, 1.26; 95% CI,
1.21-1.31]. However, the risk of hospitalization decreased with prolonged typical
use [HR, 0.90; 95% CI, 0.86-0.94]. CONCLUSIONS: Overall, typical antipsychotic us-
ers were more likely to experience all-cause hospitalization than atypical users
possibly due to differential safety profiles of antipsychotics. More research is
needed to evaluate specific reasons for the health care impact of antipsychotic use
in the elderly population.
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OBJECTIVES:About 5-12% of all pregnancies inwestern countries result in preterm
birth. Preterm born infants may be at increased risk of adverse outcomes. This
study compared hospitalization andmedication use in the first year of life between
preterm and full term born infants. METHODS: Data for this study were obtained
from linking the PHARMO database network (including detailed information on
drug dispensing and hospitalization histories) with TheNetherlands Perinatal Reg-
istry (including perinatal medical case records). From this linked cohort, all pre-
term born infants (gestational age 37 weeks) between 2004-2007 were randomly
matched to 4 full term born infants on gender, month and year of birth. All infants
were followed from birth until end of data collection in PHARMO or their first
birthday, whichever occurred first. During follow-up, hospitalization and medica-
tion use was assessed. Cox proportional hazard regression models were used to
estimate the relative risk of hospitalization/medication use among preterms com-
pared to full terms. Population attributable risk percentages (PAR%) were calcu-
lated to estimate the proportion of hospitalization/medication use attributable to
prematurity. RESULTS: Among the 71,607 singletons born between 2004-2007,
4,277 (6%) were born preterm of which 90%were hospitalized at birth, compared to
55% of the full terms. Premature infants were twice more likely to be re-hospital-
ized (RR 2.0; 95%CI 1.9-2.2), specifically for respiratory related diseases. Prematurity
accounted for 6%of respiratory re-admissions. Between the age of 6-12months, the
most frequently used outpatient drugs were antibacterials and drugs for obstruc-
tive airway diseases. Premature infants were 50%more likely to receive respiratory
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